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Suppression of neuropeptide production by
quercetin in allergic rhinitis model rats
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Abstract
Background: Quercetin, a dietary flavonoid found in many fruits, red wine and onion, among others, has been
reported to have potent anti-oxidant, anti-viral and anti-cancer effects. Although quercetin is also reported to have
anti-inflammatory and anti-allergic effects, the precise mechanisms by which quercetin favorably modify the clinical
conditions of allergic diseases such as allergic rhinitis (AR). The present study was designed to examine the
influence of quercetin on the development of AR by using AR model rats.
Methods: Sprague-Dawley (SD) rats were sensitized with toluene 2,4-diisocyanate (TDI) by intranasal instillation of a
10 % TDI in ethyl acetate in a volume of 5 μl once a day for 5 consecutive days. This sensitization procedure was
repeated after a 2-day interval. After 5 days of the second sensitization, rats were treated with various doses of
quercetin once a day for 2 to 7 days. Nasal allergy-like symptoms, which were induced by bilateral application of
5 μl of 10 % TDI in ethyl acetate, were assessed by counting sneezing and nasal rubbing behaviors for 10 min just
after TDI nasal challenge. The levels of substance P (SP), calcitonin gene-related peptide (CGRP) and nerve growth
factor (NGF) in nasal lavage fluids obtained 6 h after TDI nasal challenge was examined by ELISA.
Results: Oral administration of quercetin for 5 and 7 days, but not 2 and 3 days, could inhibit sneezing and nasal
rubbing movements, which were increased by TDI nasal challenge. The minimum dose that caused significant
inhibition was 25 mg/kg. Oral administration of quercetin at more than 25 mg/kg for 5 days significantly inhibited
the increase in SP, CGRP and NGF contents in nasal lavage fluids induced by TDI nasal challenge.
Conclusion: The present results strongly suggested that quercetin will be a good candidate for the supplement on
the management and treatment of allergic diseases, especially AR.
Keywords: Quercetin, Substance P, Calcitonin gene-related peptide, Nerve growth factor, Nasal allergy-like
symptom, Suppression, Rat
Background
Allergic rhinitis (AR) is accepted to be an IgE-mediated
inflammatory disease in the nasal mucosa and character-
ized by intense infiltration and activation of inflamma-
tory cells such as mast cells, and eosinophils, among
others [1]. Although AR is not life-threatening disease, it
can deteriorate the quality of life and an economic
burden through the clinical symptoms such as sneezing,
rhinorrhea, itching and nasal congestion [1, 2]. These
clinical conditions are well known to be primarily
induced by chemical mediators such as histamine and
leukotrienes, which are secreted by mast cells, basophils
and eosinophils [1]. In addition to the secretion of
chemical mediators, these cells also release several types
of cytokines and chemokines, which are responsible for
the amplification and the persistence of allergic inflam-
matory responses in nasal mucosa [1]. On the other
hand, there is much evidence that nasal mucosa is inner-
vated by sensory, sympathetic and parasympathetic
nerves. After stimulation with aeroallergen, sensory
nerves transmit signals generating sensations such as
itching and motor reflexes, including sneezing [3–6].
Antigenic stimulation on sensory nerves also causes
axonal reflex to produce neuropeptides, substance P
(SP) and calcitonin gene-related peptides (CGRP), which
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are responsible for vasodilation, edema and activation of
inflammatory cells in nasal mucosa [3–6].
Quercetin is one of the well-characterized flavonoids
and found in onion, red wine and mulberry, among
others [7]. It is reported that quercetin exerts many
beneficial activities on human health, including anti-
oxidative, anti-diabetic and anti-cancer activities [8–10].
In regard to allergic diseases, quercetin is reported to at-
tenuate clinical conditions of allergic diseases such as
AR through its suppressive effects on the release of in-
flammatory cytokines and chemical mediators from mast
cells and eosinophils after immunological stimulation
[11, 12]. Therapeutic potential of quercetin on allergic
airway diseases is also observed in animal experimental
models of asthma, in which oral administration of
quercetin showed the inhibitory action on bronchial
hyper-reactivity to specific allergen [13, 14]. It is also
reported that quercetin could effectively block the devel-
opment of anaphylactic responses against peanuts in the
experimental mouse model and in vitro cell lines [15,
16]. Although these reports strongly suggest that
quercetin will be a good candidate as a potential drug to
allergic diseases, the influence of quercetin on neuropep-
tide productions is poorly understood. In the present
study, therefore, we examined the influence of quercetin
on neuropeptide production by using AR model rat.
Methods
Animals
Specific pathogen free, male Sprague-Dawley (SD) rats,
5 weeks of age were purchased from CLEA JAPAN Co.,
Ltd. (Tokyo, Japan). These animals were maintained in
our animal facilities at 25 ± 2 °C with 55 ± 10 % humidity
under a 12-h light/dark cycle and were allowed free access
to tap water and standard laboratory rodent chow
(Oriental Yeast Co., Ltd., Tokyo, Japan) throughout the
experiments. Each control and each experimental group
consisted of five rats. All animal experiments were ap-
proved by the Ethics Committee for Animal Experiments
of Showa University (Approved No. 05112).
Sensitization and challenge procedures
SD rats were sensitized with toluene 2,4-diisocyanate
(TDI) according to the method described previously [17].
Briefly, 5 μl of a 10 % TDI (Wako Pure Chemicals Co.,
Ltd., Osaka, Japan) solution in ethyl acetate (Wako Pure
Chemicals Co., Ltd.) was instilled bilaterally into the nasal
vestibule once a day for 5 consecutive days. This
sensitization procedure was repeated after a 2-day interval.
To induce nasal allergy-like symptoms, 5 μl of 10 % TDI
solution in ethyl acetate was applied bilaterally on the
nasal vestibule of sensitized rats. Control rats were treated
with ethyl acetate only by the same procedure.
Treatment of rats with agents
Quercetin purchased from Sigma-Aldrich Co., Ltd. (St.
Louis, MO, USA) was well mixed with 5 % tragacanth
gum solution at a concentration of 7.5 mg/ml. Rats were
orally administered with either 10, 20, 25 or 30 mg/kg of
quercetin once a day for 2 to 7 days via a stomach tube
in a volume not exceeding 1.0 ml. Olopatadine hydro-
chloride (OH), a second generation histamine H1 recep-
tor antagonist, was used for treatment as a positive
control. OH for human use was purchased from Kyowa
Hakko Kirin Co., Ltd. (Tokyo, Japan). This was dissolved
in distilled water at a concentration of 10 mg/ml and ad-
ministered orally into rats at a dose of 10 mg/kg once a
day for 5 days via a stomach tube [19]. Treatment was
started 5 days after the final second sensitization with
TDI.
Assay for nasal symptoms
Nasal allergy-like symptoms were assessed by count-
ing numbers of sneezing and nasal rubbing move-
ments for 10 min just after TDI nasal challenge. The
experimental rats were placed into the plastic animal
cage (35 × 20 × 30 cm) for about 10 min for accli-
mation. After the nasal instillation of 10 % TDI solu-
tion in ethyl acetate in a volume of 5 μl, rats were
placed into the plastic cage (one animal/cage) and the
number of sneezes and nasal rubbing movements for
10 min were counted [19, 20].
Preparation of nasal lavage fluids
The rats were killed by intraperitoneal injection with
100 mg/kg sodium pentobarbital (Kyoritsu Seiyaku Co.,
Ltd., Tokyo, Japan) 6 h after TDI nasal challenge. The
trachea was exposed and cannulated to introduce 1.0 ml
phosphate buffered saline. The lavage fluid exiting the
nares was collected and centrifuged at 3000 rpm for
15 min at 4 °C. After measuring IgA by ELISA (Bethyl
Lab., Inc., Montgomery, TX, USA), the fluids were
stored at -40 °C until used.
Assay for neuropeptides
Substance P (SP), calcitonin gene-related peptide
(CGRP), and nerve growth factor (NGF) in nasal
lavage fluids were examined by commercially avail-
able ELISA test kits according to the manufacturer's
recommendations. SP ELISA test kits were obtained
from ENZO Life Science Inc. (Farmingdale, NY, USA),
CGRP from Phoenix Pharmaceuticals, Inc. (Burlingame,
CA, USA) and NGF from Chemicon International Inc.
(Temecula, CA, USA), and the minimum detectable levels
of these ELISA test kits was 8.04 pg/ml for SP, 0.01 ng/ml
for CGRP and 10.0 pg/ml for NGF.
Kashiwabara et al. BMC Complementary and Alternative Medicine  (2016) 16:132 Page 2 of 9
Fig. 1 Influence of quercetin on the increase in sneezing after toluene 2,4-diisocyanate (TDI) nasal instillation in sensitized rats. TDI-sensitized rats
were treated with various doses of quercetin for 2 to 7 days before TDI provocation. Olopatadine hydrochloride (OH) was administered orally into
TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation. The number of sneezing was counted for 10 min
just after TDI nasal challenge. The data are expressed as the mean ± standard errors of the means of five rats/group. NC: non-sensitized, non-
treated control; EA: ethyl acetate; OH: olopatadine hydrochloride; N.D.: not done; *: not significant (P > 0.05) as compared with EA alone, not
treated control; **: not significant (P > 0.05) as compared with TDI alone; ***: significant (P < 0.05) as compared with TDI alone
Fig. 2 Influence of quercetin on the increase in nasal rubbing by toluene 2,4-diisocyanate (TDI) nasal instillation in sensitized rats. TDI-sensitized
rats were treated with various doses of quercetin for 2 to 7 days before TDI provocation. Olopatadine hydrochloride (OH) was administered orally
into TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation. The number of nasal rubbing was counted for
10 min just after TDI nasal challenge. The data are expressed as the mean ± standard errors of the means of five rats/group. NC: non-sensitized,
non-treated control; EA: ethyl acetate; OH: olopatadine hydrochloride; N.D.: not done; *: not significant (P > 0.05) as compared with EA alone, not
treated control; **: not significant (P > 0.05) as compared with TDI alone; ***: significant (P < 0.05) as compared with TDI alone
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Statistical analysis
The results are shown as the mean ± standard errors of
the means (SEM) of five rats/group. Statistical analyses
were performed with analysis of variance (ANOVA)
followed by Bonferroni correction. A value of P < 0.05
was considered statistically significant.
Results
Influence of quercetin on the development of TDI-
induced nasal allergy-like symptoms
The first set of experiments was undertaken to exam-
ine whether oral administration of quercetin into
TDI-sensitized rats could inhibit the development of
nasal allergy-like symptoms, which was induced by
nasal antigenic challenge. Nasal symptoms were
assessed by counting the numbers of sneezes and
nasal rubbing movements for 10 min just after TDI
nasal challenge. As shown in Fig. 1, treatment of
TDI-sensitized rats with quercetin for 2 and 3 days
could not suppress the development of sneezing in-
duced by TDI provocation, even when 30 mg/kg/day
of quercetin was used for treatment. However, oral
administration of quercetin at more than 25 mg/kg,
but not 10 mg/kg and 20 mg/kg, for 5 and 7 con-
secutive days inhibited the development of sneezing:
the numbers of sneezing observed in rats treated with
10 and 20 mg/kg quercetin are nearly identical (not
significant) to that in TDI-sensitized, not treated rats
but the sneezing observed in TDI-sensitized rats
treated with quercetin at 25 mg/kg and more is sig-
nificantly lower than control rats (Fig. 1). The data in
Fig. 1 also showed the suppressive activity of OH, a
histamine-H1 receptor antagonist, which is used as a
positive control, on the development of sneezing. We
then examined the influence of quercetin on nasal
rubbing movements induced by TDI nasal challenge.
As shown in Fig. 2, oral administration of quercetin
at more than 25 mg/kg for 5 and 7 consecutive days,
but not 2 and 3 days, significantly suppressed the de-
velopment of nasal rubbing movements and the num-
ber of movements were much lower than that
observed in TDI-sensitized, non-treated rats (P <
0.05). The data in Fig. 2 also showed the attenuating
effect of OH on the development of nasal rubbing
movements induced by TDI provocation: the number
of movements in TDI-sensitized rats treated with
Fig. 3 Influence of quercetin on the appearance of substance P (SP) in nasal lavage fluids after toluene 2,4-diisocyanate (TDI) nasal instillation in
sensitized rats. TDI-sensitized rats were treated with 25 mg/kg quercetin for 2 to 7 days before TDI provocation. Olopatadine hydrochloride (OH)
was administered orally into TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation. The levels of SP in
nasal lavage fluids obtained from sensitized rats 6 h after TDI nasal challenge were measured by ELISA. The data are expressed as the mean
pg/ng IgA ± standard errors of the means of five rats/group. NC: non-sensitized, non-treated control; EA: ethyl acetate
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olopatadine was significantly lower than control rats
(P < 0.05).
Influence of quercetin on neuropeptide appearance in
nasal lavage fluids obtained from TDI-sensitized rats
The second set of experiments was undertaken to
examine the duration of quercetin treatment on the
appearance of neuropeptides in nasal lavage fluids ob-
tained from sensitized rats after TDI nasal challenge.
To do this, TDI-sensitized rats were orally adminis-
tered quercetin at 25 mg/kg, which is the minimum
concentration showing the suppressive effects on the
development of nasal symptoms, for 2 to 7 consecu-
tive days before the challenge. Nasal lavage fluids
were obtained from rats 6 h after the challenge and
SP levels were examined by ELISA. As shown in
Fig. 3, oral administration of quercetin for more than
5 days significantly inhibited the increase in SP levels
in nasal lavage fluids, which was increased by intrana-
sal challenge with TDI. We then examine the dose re-
sponse profile of quercetin on the appearance of SP
in nasal lavage fluids. TDI-sensitized rats were orally
administered various doses of quercetin for five con-
secutive days before the challenge. Nasal lavage fluids
were obtained from rats 6 h after the challenge and
SP levels were examined by ELISA. As shown in
Fig. 4, oral administration of quercetin at more than
25 mg/kg caused significant decrease in SP levels in
nasal lavage fluids, which was increased by TDI nasal
challenge. It is also showed that oral administration
of OH at 10 mg/kg for 5 days could inhibit increase
in SP levels in nasal lavage fluids after TDI nasal
challenge (Fig. 4). We then examined whether quer-
cetin and OH could also suppress the appearance of
neuropeptides, CGRP and NGF, in nasal lavage fluids
after TDI nasal challenge as in the case of SP. TDI-
sensitized rats were orally administered various doses
of quercetin or 10 mg/kg OH for 5 days before the
challenge. Nasal lavage fluids were obtained from rats
6 h after the challenge and the levels of CGRP and
NGF were examined by ELISA. As shown in Fig. 5,
oral administration of quercetin at more than 25 mg/
kg into TDI-sensitized rats could decrease CGRP level
in nasal lavage fluids, which was increased by TDI
nasal challenge. It is also showed the suppressive ef-
fect of 10 mg/kg OH on CGRP appearance in nasal
fluids after TDI nasal challenge (Fig. 5). Furthermore,
oral administration of quercetin at more than 25 mg/
kg into TDI-sensitized rats could also significantly
suppress the increase in NGF contents in nasal lavage
fluids after TDI nasal challenge as well as 10 mg/kg
OH (Fig. 6).
Fig. 4 Influence of quercetin on the appearance of substance P (SP) in nasal lavage fluids after toluene 2,4-diisocyanate (TDI) nasal instillation in
sensitized rats. TDI-sensitized rats were treated with various doses of quercetin for 5 days before TDI provocation. Olopatadine hydrochloride (OH)
was administered orally into TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation. The levels of SP in
nasal lavage fluids obtained from sensitized rats 6 h after TDI nasal challenge were measured by ELISA. The data are expressed as the mean
pg/ng IgA ± standard errors of the means of five rats/group. NC: non-sensitized, non-treated control; EA: ethyl acetate
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Discussion
AR is a global health problem that affects patients of
all ages and characterized mainly by the three car-
dinal symptoms such as sneezing, nasal obstruction
and watery rhinorrhea [1, 2]. These clinical symptoms
are considered to be caused by the chemical media-
tors such as histamine, prostaglandins and leukotriens
secreted from inflammatory cells especially mast cells
[1, 2]. In addition to the development of clinical
symptoms, these mediators stimulate sensory nerves
to release several types of neuropeptides which in
turn produce itching, nasal congestion and sneezing
[3–6]. From these established concepts, histamine H1
receptor antagonists are recommended as a first
choice of the agents for AR treatment as well as top-
ical corticosteroids [2]. On the other hand, there is
much evidence that oral administration of quercetin
and its derivative, isoquercetin, into allergic patients
could modify favorably the clinical conditions of the
diseases and the therapeutic mode of quercetin may
be owing, at least in part, to its suppressive effects on
inflammatory cell (e.g. mast cells and eosinophils) ac-
tivation [11, 12]. However, the influence of quercetin
on the production of neuropeptides, which are re-
sponsible for the development of clinical symptoms of
AR, is not fully understood. The present study, therefore,
was undertaken to examine the influence of quercetin on
neuropeptide production using TDI-sensitized rats.
The present results clearly showed that oral adminis-
tration of quercetin at more than 25 mg/kg for 5 days
into TDI-sensitized rats significantly inhibited the devel-
opment of nasal allergy-like symptoms such as sneezing
and nasal rubbing movements, which are induced by
nasal antigenic challenge. The clinical nasal allergic reac-
tion is divided into the early (or immediate)- and the
late-phase response [2]. The early phase-allergic re-
sponse is occurred within minutes of allergen exposure
and characterized by sneezing, nasal itching and watery
rhinorrhea, which are mainly caused by the chemical
mediators secreted from mast cells and basophils [2]. It
is also reported that the chemical mediators stimulate
nasal sensory neurons to cause sneezing reflax via the
central nervous system [3, 4, 6]. There is also a local
effect, so called axonal reflax, in which sensory nerves
release several types of neuropeptides such as SP and
CGRP, leading to vasodilation and plasma exudation [3,
4, 6]. These responses originated in sensory nerve activa-
tion are called neurogenic inflammation [4]. Intranasal
instillation of TDI into rats is well accepted to induce
nasal neurogenic inflammation and used frequently for
analysis the mechanisms of nasal neurogenic inflamma-
tion [17–19]. Together with these reports, the present
Fig. 5 Influence of quercetin on the appearance of calcitonine gene-related peptide (CGRP) in nasal lavage fluids after toluene 2,4-diisocyanate (TDI)
nasal instillation in sensitized rats. TDI-sensitized rats were treated with various doses of quercetin for 5 days before TDI provocation. Olopatadine
hydrochloride (OH) was administered orally into TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation. The
levels of CGRP in nasal lavage fluids obtained from sensitized rats 6 h after TDI nasal challenge were measured by ELISA. The data are expressed as the
mean ng/ng IgA ± standard errors of the means of five rats/group. NC: non-sensitized, non-treated control; EA: ethyl acetate
Kashiwabara et al. BMC Complementary and Alternative Medicine  (2016) 16:132 Page 6 of 9
results may be interpreted that oral administration of
quercetin into TDI-sensitized rats attenuates the devel-
opment of nasal neurogenic inflammation and results in
inhibition of the development of nasal allergy-like symp-
toms induced by TDI nasal provocation in rats.
The second part of experiments was undertaken to
evaluate the influence of quercetin on the development
of nasal neurogenic inflammation by examining the con-
tents of neuropeptides in nasal lavage fluids. The present
data clearly showed that oral administration of quercetin
at more than 25 mg/kg for 5 days could significantly in-
hibit the appearance of neuropeptides, SP, CGRP and
NGF in response to TDI nasal challenge. SP and CGRP
act synergistically and increase each other mast cell de-
granulation to produce chemical mediators responsible
for development of the early-phase allergic response [6,
21]. These two neuropeptides also activate macrophages
to produce pro-inflammatory cytokines, including inter-
leukin (IL)-1β, IL-3 and TNF-α, which are functioned in
additional stimulus to allergic inflammation [22, 23].
Furthermore, SP increases the ability of sensory nerves
and nasal epithelial cells to produce NGF [24, 25], which
contributes to amplifying the early-phase allergic re-
sponse through the promotion of both survival and de-
granulation of mast cells [6, 25]. NGF also activates
tyrosine kinase A (TrkA) receptor which in turn initiates
signaling via the phosphatidylinositol 3 kinase/phos-
phatidylinositol phosphate 3 (PI3K/PIP3) pathway to in-
crease expression and sensitivity of transient receptor
potential vallinoid (TRPV1) receptor, which is respon-
sible for the production and release of SP and CGRP
from sensory neurons [6]. These reports may suggest
that oral administration of quercetin at more than
25 mg/kg for 5 days into TDI-sensitized rats inhibit
neuropeptide productions from sensory neurons and re-
sults in attenuation of the appearance of nasal allergy-
like symptoms induced by TDI nasal provocation.
Although the present results strongly suggest that quer-
cetin attenuates nasal allergy-like symptoms through the
suppression of neuropeptide release after antigenic chal-
lenge, the precise mechanisms by which quercetin inhibits
neuropeptide production from sensory nerves after anti-
genic challenge. It is reported that the activation of the
extracellular signal-regulated kinase 1/2 (ERK1/2) pathway
is essential for the production of both SP and CGRP in dor-
sal root ganglions and peripheral nerve fibers [26]. The acti-
vation of ERK1/2 and nuclear factor-κB (NF-κB) pathway is
also reported to enhance SP production and is responsible
for the development of neurogenic inflammation [26, 27].
Furthermore, NGF production in keratinocytes requires the
activation of mitogen-activated protein kinase (MAPK), es-
pecially ERK1/2, and phosphorylation of NF-κB after
Fig. 6 Influence of quercetin on the appearance of nerve growth factor (NGF) in nasal lavage fluids after toluene 2,4-diisocyanate (TDI) nasal
instillation in sensitized rats. TDI-sensitized rats were treated with various doses of quercetin for 5 days before TDI provocation. Olopatadine
hydrochloride (OH) was administered orally into TDI-sensitized rats once a day for 5 days at a single dose of 10 mg/kg before the provocation.
The levels of NGF in nasal lavage fluids were measured by ELISA. The data are expressed as the mean pg/ng IgA ± standard errors of the means
of five rats/group. NC: non-sensitized, non-treated control; EA: ethyl acetate
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stimulation with SP, CGRP and other inflammatory media-
tors [28]. Neuropeptides synthetized in the neuron cell
body are stored in vesicles and the vesicles are transported
to the release sites such as the axon terminals [29]. When
an action potential reaches the axon terminals, Ca2+ is in-
flux into the axon terminals through Ca2+ channels and in-
creases the intracellular Ca2+ concentrations. And then
neuropeptides are released by exocytosis to the extracellular
space [28, 29]. It is reported that Ca2+ is an essential mol-
ecule for activation of both MAPK, including ERK1/2 and
NF-κB after stimulation of cells with inflammatory mole-
cules such as cytokines and neuropeptides [30]. Quercetin
is reported to increase in intracellular Ca2+ contents after
compound 48/80 stimulation in human mast cell line in
vitro [31]. From these reports, there is possibility that oral
administration of quercetin into TDI-sensitized rats inhibits
changes in Ca2+ contents in the axon terminals after TDI
nasal challenge and results in suppression of neuropeptide
appearance in nasal lavage fluids.
Allergic diseases such as AR, asthma and atopic derma-
titis (AD) are characterized by intense infiltration and acti-
vation of Th2 T-cells, mast cells and eosinophils into the
inflamed tissues. Th2 T-cells are believed to orchestrate
the development and maintenance of allergic inflamma-
tory responses through the secretion of inflammatory cy-
tokines such as IL-3, IL-5 and thymus and activation-
regulated chemokine (TARC), which are responsible for
promotion of migration and activation of inflammatory
cells, including mast cells and eosinophils [1]. It is re-
ported that quercetin at 5.0 μM significantly suppressed
TARC production from human keratinocytes, HaCat cell
after TNF-α stimulation in vitro [32]. Oral administration
of 2.5 mM quercetin three times a week for 3 weeks into
AD experimental model mouse, Nc/Nga is also reported
to decrease serum TARC levels along with attenuation of
clinical symptoms [32]. Furthermore, there is evidence
that quercetin at 5.0 μM significantly suppresses eosino-
phil degranulation and the ability of eosinophil to produce
chemokines such as eotaxin, RANTES and MIP-1β, which
are implicated in development and persistence of eosino-
philic inflammatory responses [1], after immunological
and no-immunological stimulations in vitro [11, 12, 33–
35]. In regard to mast cells functions, quercetin inhibits
the release of histamine and several types of inflammatory
cytokines responsible for the development of allergic re-
sponses [8, 35–37]. Together with these reports and the
present results, it is strongly suggest that quercetin modu-
lates the activation of inflammatory cells and neuropeptide
productions and results in improvement of clinical condi-
tions of allergic diseases, especially AR.
Conclusion
The present results clearly showed the attenuating
effects of quercetin on nasal allergy-like symptoms
induced by neurogenic inflammation through the sup-
pression of neuropeptide production in vivo. Thus, quer-
cetin will be a useful supplement for the management
and treatment of AR.
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